• Clinical Program Oversight (Phase I?IIb): Strategic lead for global vendor landscapes (CROs, Specialty Labs, Depots); directed Bid Defense and contract negotiations to secure Sponsor Data Sovereignty and absolute milestone adherence. 
• Core Dossier Architecture & Writing: Designed and authored the complete regulatory suite (CDP, CTP, IB, IMPD) for novel IVDR biomarkers; spearheaded Phase IIb submissions via EU-CTIS and managed EMA Scientific Advice meetings.
• Analytical & Digital Governance: Orchestrated the integration of Mass Spectrometry (HRMS) and Metabolomics into protocols; leveraged Digital Twins for predictive modeling to establish robust IRT/EDC system specifications (including robust UAT).
• Operational & Supply Excellence: Managed global lab & ancillary forecasts, shipment logistics, and DSMB/IDMC frameworks; developed company-wide Quality Management Systems (QMS) and SOPs to ensure inspection readiness.

• Clinical Program Leadership (Phase I & III): Strategic lead for global biosimilar programs; directed the operational PK/PD study execution (SAD/MAD) and managed parallel Phase III Mega-Trial milestones, budgets, and Sponsor Oversight.
• Strategic Vendor & CRO Governance: Led the end-to-end selection of CROs, Phase I units, and depots; conducted rigorous Bid Defense meetings and negotiated MSA/SoWs to align technical interfaces with global clinical operations.
• CMC & Supply Orchestration: Primary liaison to synchronize internal manufacturing (CDMO) timelines with clinical supply requirements; authored and updated IMPDs, IBs, and CTPs for regulatory filing strategies.
• Integrated Data & Validation Oversight: Directed the eCRF & IRT/IVRS setup; supervised analytical assay development (PK/ADA) and led high-complexity UAT cycles at external CROs to ensure absolute GxP compliance.

• Clinical Program & Consortium Leadership: Strategic lead for the EU-funded ENABLE (IMI) project; orchestrated clinical development for "Last Resort Antibiotics" within a high-stakes global research consortium and led the Consortium governance.
• Early Phase Execution (Phase 1a): Directed the operational PK/PD study execution (SAD/MAD); established the Therapeutic Profile Plan (TPP) and managed all sponsor-side documents (IMPD S-Part/P-Part, IB, CTP) for regulatory submission.
• Regulatory Liaison & Strategy: Authored and coordinated the Scientific Advice booklets for national (BfArM) and international (EMA ITF) meetings; responsible for CSR approval, submission, and final TMF archiving.
• System & Supply Orchestration: Managed the global CMC research network and Master Label Release; implemented accelerated IRT/IVRS setups and bedside mixing supply plans to meet aggressive FPI and CSR timelines.

• Regulatory Strategy & Device Ops (GSOmbh): Directed the global regulatory strategy for a multi-country organ transplantation study (10 countries) under MDR 3.0; spearheaded the TMF transformation to DIA structure to enhance inspection readiness and operational efficiency.
• Clinical Monitoring & Oncology (GSOmbh): Performed high-level site monitoring (CRA) for neo-adjuvant oncology trials; ensured rigorous adherence to ICH-GCP and national guidelines for complex cancer research protocols.
• Strategic Medical Writing (Appletree CRO): Executed a high-stakes Regulatory Rescue (CER) for a Class III medical device to secure market access; authored full-stack documentation including IMPDs, IBs, CTPs, and ICFs across multiple indications.
• Digital Health & Patient Recruitment (Mondosano): Developed patient registry frameworks according to CDISC standards; integrated Google Analytics into documentation cycles to optimize digital recruitment workflows and patient-lead generation.

• Clinical-to-Market Transition: Strategic lead for the operational transition from clinical development to market authorization; orchestrated the setup of Compassionate Use Programs and Investigator-Initiated Trials (IITs).
• Mega-Trial Operations & Site Management: Directed the operational roll-out and Sponsor Oversight for 54 sites across CEE, Russia, and Ukraine; managed multi-million Euro budgets and ensured rigorous adherence to Phase III registration timelines.
• Complex IRT & EDC System Pivot: Engineered the critical IRT/EDC logic adaptation to transition short-term registration data into a 6-year long-term study, ensuring seamless data continuity (Besremi®).
• Molecular Innovation (NGS/SNP): Pioneered the integration of Next-Generation Sequencing (NGS) and SNP data workflows into the clinical IT infrastructure.

Global Phase II/III Vaccine Programs

• Global Trial Execution & Operations: End-to-end responsibility for the operational roll-out of global Mega Trials, directed all study phases from Site Feasibility to Database Lock, managed 950+ site visits and 120 CRA assessment visits.
• Operational IRT/IwRS Integration: Orchestrated the first EU-wide IwRS implementation; engineered blinding schemes and randomization triggers specifically for complex vaccine trials.
• Clinical Supply & CDMO Orchestration: Cross-functional lead for global IMPD/CDMO management, accountable for IMP and ancillary supply forecasting, labeling, and real-time IVRS supply-integration.
• Matrix Leadership & Inspection Readiness: Directed a global landscape of vendors; acted as Back-office Lead for EMA/FDA inspections for BLA/MAA submissions.